The Role of Serotonin in Depression and Clotting in the Coronary Artery Disease Population

Sanner, Jennifer E.; Frazier, Lorraine

doi:10.1097/jcn.0b013e3182076a81

Cited by 20 publications

(16 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the recent years, the elevated comorbidity rates between cardiovascular disease and depression have occasioned several investigations on the link between them. [ 17 18 ] Our previous studies[ 19 20 ] showed that 5-HT-enhanced platelet activation emerged from this work as a leading candidate explanation of the elevated cardiac risk that attended a diagnosis of major depression.…”

Section: Discussionmentioning

confidence: 91%

5-Hydroxytryptamine Changes under Different Pretreatments on Rat Models of Myocardial Infarction and/or Depression

Zhang

Zhou

Wei

2017

Chinese Medical Journal

View full text Add to dashboard Cite

Background:Psychocardiological researches have suggested a central role of 5-hydroxytryptamine (5-HT) on psychocardiological mechanism. This study aimed to further explore the central role of 5-HT and pretreatment effects of XinLingWan on rats with myocardial infarction (MI) and/or depression.Methods:Ninety Sprague-Dawley rats were randomly divided into three groups: MI group, depression group, and MI + depression group (n = 30 in each group). Each group was then divided into three subgroups (n = 10 in each subgroup): a negative control subgroup (NCS), a Western medicine subgroup (WMS), and a traditional Chinese medicine subgroup (TCMS), which were received pretreatment once a day for 4 weeks by saline, 20 mg/kg sertraline mixed with 2 ml saline, and 40 mg/kg XingLingWan mixed with 2 ml saline, respectively. Different rat models were established after different pretreatments. Rats were then sacrificed for detection of serum 5-HT, platelet 5-HT, 5-HT2A receptors (5-HT2AR), and serotonin transporter (SERT). Data were analyzed by one-way analysis of variance (ANOVA) and least-significant difference (LSD) testing.Results:MI group: compared with NCS, there was a significant increase in WMS and TCMS of serum 5-HT (176.15 ± 11.32 pg/ml vs. 334.50 ± 29.09 pg/ml and 474.04 ± 10.86 pg/ml, respectively, both P = 0.000), platelet 5-HT (129.74 ± 27.17 pg/ml vs. 322.24 ± 11.60 pg/ml and 340.4 5 ± 17.99 pg/ml, respectively, both P = 0.000); depression group: compared with NCS, there was a significant increase in WMS and TCMS of serum 5-HT (194.69 ± 5.09 pg/ml vs. 326.21 ± 39.98 pg/ml and 456.33 ± 23.12 pg/ml, respectively, both P = 0.000), platelet 5-HT (175.15 ± 4.07 pg/ml vs. 204.56 ± 18.59 pg/ml and 252.03 ± 22.26 pg/ml, respectively, P = 0.004 and P = 0.000, respectively); MI + depression group: compared with NCS, there was a significant increase in both WMS and TCMS of serum 5-HT (182.50 ± 10.23 pg/ml vs. 372.55 ± 52.23 pg/ml and 441.76 ± 23.38 pg/ml, respectively, both P = 0.000) and platelet 5-HT (180.83 ± 11.08 pg/ml vs. 221.12 ± 22.23 pg/ml and 265.37 ± 29.49 pg/ml, respectively, P = 0.011 and P = 0.000, respectively).Conclusions:By elevating the amount of 5-HT and modulating 5-HT2AR and SERT levels in serum and platelets, XinLingWan and sertraline were found to exert pretreatment effect on rat models of MI and/or depression.

show abstract

Section: Discussionmentioning

confidence: 91%

5-Hydroxytryptamine Changes under Different Pretreatments on Rat Models of Myocardial Infarction and/or Depression

Zhang

Zhou

Wei

2017

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…Alterations in the serotonergic system might also explain the link between MD and CAD (10,27). In addition to a central serotonin deficit (28), alterations in peripheral serotonin levels have been suggested: most of peripheral serotonin (5-hydroxy-tryptamine; 5-HT) is stored in platelets and released during platelet activation (29).…”

Section: Introductionmentioning

confidence: 99%

Cortisol, Platelet Serotonin Content, and Platelet Activity in Patients With Major Depression and Type 2 Diabetes

Zahn

Petrak

Franke

et al. 2015

Psychosomatic Medicine

View full text Add to dashboard Cite

Increased platelet activity in T2DM and MD may play a role in the association between diabetes, depression, and coronary artery disease. The present data suggest that group differences in cortisol or 5-HT as well as group-specific associations of cortisol or 5-HT with platelet markers might be of limited importance in the shared pathways of T2DM and depression in the pathophysiology of coronary artery disease.

show abstract

“…The data for individual SIPPS suggest that, for example, sertraline in vitro causes the inhibition of thrombocyte aggregation, depending on its dose [52]. After six weeks of therapy with paroxetine, a normalization of thrombocyte activity can be observed in depressive patients, both in those with and those without the coronary heart disease [53]. Similarly.…”

Section: Discussionmentioning

confidence: 92%

The role of thrombocyte serotonin system and some thrombocyte characteristics in treatment of depressive patients with cardiovascular diseases

Kostanjšak¹,

Zdunić

2017

Alcoholism and Psychiatry Research

View full text Add to dashboard Cite

-Serotonin has an important role in the development of depressive disorders. Bearing in mind that direct testing of central nervous system is unavailable to researchers due to the inability to reach the samples, ever greater attention is given to the peripheral systems that can help us diagnose and detect changes of the disease, but also follow the course of its treatment and recovery. Thrombocyte is a blood cell that contains serotonin lodged in its delta granules. Thrombocyte serotonin system is similar, although not the same as the serotonin system in central nervous system. The most important differences are that in thrombocytes, serotonin is broken down by the enzyme monoaminooxidase B (MAO-B), while that function in neuron is carried out by monoaminooxidase A (MAO-A) and that a thrombocyte cannot synthetize serotonin itself, because it lacks tryptophan hydroxylase. Nowadays, in the treatment of depressive disorders, mostly the selective inhibitors of serotonin uptake (SIPPS) are being used. The research has proved that therapy with those medications changes the concentration of serotonin in thrombocytes and changes the values of some thrombocyte indices. The thrombocyte serotonin is a powerful vasoconstrictor, which increases the cardiovascular risk and the probability of thrombogenesis. The mean volume of thrombocytes (MPV) is a positive index of thrombocyte activity and the increase of MPV represents an independent risk factor for the development of cardiovascular diseases. It is of enormous significance to recognize the depression in patients who suffer from cardiovascular diseases. Depression interferes with the recovery of those patients, because it reduces the personal engagement in it and disturbs patients' compliance and the motivation for treatment. Besides the fact that the treatment with SIPPS leads to the regression of symptoms of depression, it also changes the concentration of thrombocyte serotonin and the mean volume of thrombocytes towards the values that reduce their role in pathogenesis of cardiovascular diseases, thus reducing the risk of re-occurrence of cardiovascular incidents and improving the patients' recovery.

show abstract

The Role of Serotonin in Depression and Clotting in the Coronary Artery Disease Population

Cited by 20 publications

References 41 publications

5-Hydroxytryptamine Changes under Different Pretreatments on Rat Models of Myocardial Infarction and/or Depression

5-Hydroxytryptamine Changes under Different Pretreatments on Rat Models of Myocardial Infarction and/or Depression

Cortisol, Platelet Serotonin Content, and Platelet Activity in Patients With Major Depression and Type 2 Diabetes

The role of thrombocyte serotonin system and some thrombocyte characteristics in treatment of depressive patients with cardiovascular diseases

Contact Info

Product

Resources

About